Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 19, 2013

View Archived Issues

Isis earns milestone payment from GSK for designation of new development candidate

Antibody fragment-mediated eradication of hallmark Alzheimer-like pathology in transgenic mice

A comparison of systemic and macrophage receptor-targeted delivery of an anti-inflammatory drug

Ligase inhibitors that inhibit hormone-induced growth of endometrial cancer

First clinical data presented for ISIS-APOARx

Relvar Ellipta approved in Europe for asthma and COPD

Lupin discloses novel CRAC modulators

Pharmacokinetic data on novel natriuretic peptide ANX-042 reported

Suven presents novel candidates for cognitive deficits associated with degenerative diseases

Cellceutix identifies drug candidates for infections, completing IND for antipsoriatic drug

Novartis synthesizes new series of complement factor B inhibitors

FDA grants priority review to Merck & Co.'s NDA for intravenous Noxafil

RedHill Biopharma provides regulatory update for RHB-103

Columbia University prepares new RBP4 antagonists for AMD

Actinium Pharmaceuticals provides update on Iomab-B and Actimab-A

Researchers in Alabama synthesize novel LRRK2 inhibitors

Aileron Therapeutics secures financing to advance pipeline

A team of scientists at Merck KGaA disclose novel pyrrolotriazinone derivatives

Corgenix files concurrent de novo 510 pre-market notification for Hyaluronic Acid Test Kit

Qiagen and Lilly in new agreement to develop companion diagnostic for oncology compound

Generex Biotechnology reaches prespecified point in phase II trial of breast cancer vaccine

Teva Pharmaceutical provides updates to oncology biologic portfolio

Results from phase IIIb study of Xiaflex for Dupuytren's contracture with multiple palpable cords

European approval for Vitekta

European Commission approves Prilocaine Lidocaine Plethora for premature ejaculation

Kyorin launches Flutiform in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 9, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...